Literature DB >> 24980077

Influence of cardiovascular risk factors on levels of matrix metalloproteinases 2 and 9 in human abdominal aortic aneurysms.

J-F Dilmé1, S Bellmunt1, M Camacho2, D Solà-Villà3, J-M Romero1, J-R Escudero1, L Vila4.   

Abstract

OBJECTIVE: To evaluate the influence of cardiovascular risk factors on levels of matrix metalloproteinases (MMP) 2 and 9 in human abdominal aortic aneurysms (AAA).
METHODS: Aortic samples were collected from patients who underwent AAA repair (n = 89). Patients were stratified according to the maximum transverse aorta diameter: small diameter (<55 mm), moderate diameter (55-69.9 mm) and large diameter (≥70 mm). Aortic walls were studied using real-time PCR and immunohistochemistry. MMP-2, MMP-9, α-actin, CD45, and CD68 transcript levels were determined relative to β-actin. Quantitative data were expressed as median (IQ-range).
RESULTS: No differences were found in MMP-2 expression between the patient groups, which was mainly associated with vascular smooth muscle cells (VSMC); however, MMP-9 displayed the maximum level in the moderate-diameter group, associated with infiltrating macrophages. Current smoking (CS) and renal insufficiency (RI) significantly increased local levels of MMP-2 (CS 349.5 [219.5-414.1] vs. no-CS 184.4 [100.0-320.5]; p < .008; RI 286.8 [189.6-410.8] vs. no-RI 177.3 [99.3-326.9]; p = .047). Nevertheless, after stepwise linear regression analysis only CS remained as an independent variable predicting local levels of MMP-2 (p = .002). No risk factors influenced local levels of MMP-9.
CONCLUSIONS: The results show that local levels of MMP-2, an important factor for AAA development, were increased in current smoking AAA patients. MMP-2 was mainly associated with VSMC. It is suggested that MMP-2 could contribute significantly to the increased AAA growth rate observed in current smoking patients. These findings support inclusion of smokers in screening for aneurysmal disease, and emphasize the need for more aggressive monitoring of aneurysmal disease outside the surgical range in patients who smoke at the time of diagnosis and in those who continue to smoke during follow-up.
Copyright © 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Abdominal aortic aneurysm; Cardiovascular risk factors; MMP-2; Tobacco smoking

Mesh:

Substances:

Year:  2014        PMID: 24980077     DOI: 10.1016/j.ejvs.2014.05.023

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  11 in total

1.  Identification and characterization of CD4(+)AT2(+) T lymphocyte population in human thoracic aortic aneurysm.

Authors:  Chenxi Wang; Ting Wu; Xiaojuan Hu; Ritai Huang; Feng Lian; Weijun Wang; Yuan Feng; Bo Xie; Zhenlei Hu; Xinming Zhai; Jidong Liu; Jianmin Gu; Yao Chen; Jun Li; Song Xue
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

Review 2.  Abdominal aortic aneurysm: novel mechanisms and therapies.

Authors:  Frank M Davis; Debra L Rateri; Alan Daugherty
Journal:  Curr Opin Cardiol       Date:  2015-11       Impact factor: 2.161

3.  Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo.

Authors:  Qiongxin Wang; Ye Ding; Ping Song; Huaiping Zhu; Imoh Okon; Yang-Nan Ding; Hou-Zao Chen; De-Pei Liu; Ming-Hui Zou
Journal:  Circulation       Date:  2017-10-04       Impact factor: 29.690

4.  Inducible Depletion of Calpain-2 Mitigates Abdominal Aortic Aneurysm in Mice.

Authors:  Latha Muniappan; Michihiro Okuyama; Aida Javidan; Devi Thiagarajan; Weihua Jiang; Jessica J Moorleghen; Lihua Yang; Anju Balakrishnan; Deborah A Howatt; Haruhito A Uchida; Takaomi C Saido; Venkateswaran Subramanian
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-25       Impact factor: 8.311

5.  Chronic Kidney Disease Is Positively and Diabetes Mellitus Is Negatively Associated with Abdominal Aortic Aneurysm.

Authors:  Hidemi Takeuchi; Michihiro Okuyama; Haruhito A Uchida; Yuki Kakio; Ryoko Umebayashi; Yuka Okuyama; Yasuhiro Fujii; Susumu Ozawa; Masashi Yoshida; Yu Oshima; Shunji Sano; Jun Wada
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

6.  Circulating CCL20 as a New Biomarker of Abdominal Aortic Aneurysm.

Authors:  B Soto; T Gallastegi-Mozos; C Rodríguez; J Martínez-González; J-R Escudero; L Vila; M Camacho
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

7.  Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions.

Authors:  Jéssica Cavalcante Dos Santos; Marina Sampaio Cruz; Raul Hernandes Bortolin; Katiene Macêdo de Oliveira; Jéssica Nayara Góes de Araújo; Victor Hugo Rezende Duarte; Ananília Medeiros Gomes da Silva; Isabelle Cristina Clemente Dos Santos; Juliana Marinho de Oliveira Dantas; Maria Sanali Moura de Oliveira Paiva; Adriana Augusto Rezende; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata; André Ducati Luchessi; Vivian Nogueira Silbiger
Journal:  Clinics (Sao Paulo)       Date:  2018-05-28       Impact factor: 2.365

8.  Bazedoxifene Attenuates Abdominal Aortic Aneurysm Formation via Downregulation of Interleukin-6/Glycoprotein 130/Signal Transducer and Activator of Transcription 3 Signaling Pathway in Apolipoprotein E-Knockout Mice.

Authors:  Dan Yan; Haiyan Ma; Wei Shi; Pengcheng Luo; Tianshu Liu; Junyi Guo; Maocai Zhai; Jingwen Tao; Shengqi Huo; Chenglong Li; Jiayuh Lin; Sheng Li; Jiagao Lv; Cuntai Zhang; Li Lin
Journal:  Front Pharmacol       Date:  2020-04-17       Impact factor: 5.810

9.  Fluoroquinolones increase the risk of aortic aneurysm and dissection: A protocol for meta-analysis.

Authors:  Jiawei Zhang; Zhe Zhang
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

10.  The elevated expression of TLR4 and MMP9 in human abdominal aortic aneurysm tissues and its implication.

Authors:  Tan Li; Xintong Li; Xiaozheng Liu; Jun Yang; Chunyan Ma
Journal:  BMC Cardiovasc Disord       Date:  2021-08-04       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.